BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17696576)

  • 1. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme : a meta-analysis.
    Spiegel BM; Esrailian E; Laine L; Chamberlain MC
    CNS Drugs; 2007; 21(9):775-87. PubMed ID: 17696576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distance to the neurooncological center: a negative prognostic factor in patients with glioblastoma multiforme. An epidemiological study.
    Kerschbaumer J; Freyschlag CF; Bauer R; Obwegeser AA; Schubert GA; Thomé C; Seiz M
    Anticancer Res; 2012 Dec; 32(12):5515-9. PubMed ID: 23225460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
    Kim YH; Kim T; Joo JD; Han JH; Kim YJ; Kim IA; Yun CH; Kim CY
    Cancer; 2015 Sep; 121(17):2926-32. PubMed ID: 25975354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
    Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
    Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
    Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
    Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
    Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
    J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.
    Xing WK; Shao C; Qi ZY; Yang C; Wang Z
    Drug Des Devel Ther; 2015; 9():3341-8. PubMed ID: 26170620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
    Olson JJ; Nayak L; Ormond DR; Wen PY; Kalkanis SN;
    J Neurooncol; 2014 Jul; 118(3):501-55. PubMed ID: 24740194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
    Dixit S; Hingorani M; Achawal S; Scott I
    Br J Neurosurg; 2011 Aug; 25(4):459-69. PubMed ID: 21344976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies.
    Wang Y; Feng Y
    Clin Neurol Neurosurg; 2020 Sep; 196():105890. PubMed ID: 32623215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas.
    Rhee DJ; Kong DS; Kim WS; Park KB; Lee JI; Suh YL; Song SY; Kim ST; Lim DH; Park K; Kim JH; Nam DH
    Clin Neurol Neurosurg; 2009 Nov; 111(9):748-51. PubMed ID: 19716649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
    Groves MD; Puduvalli VK; Chang SM; Conrad CA; Gilbert MR; Tremont-Lukats IW; Liu TJ; Peterson P; Schiff D; Cloughesy TF; Wen PY; Greenberg H; Abrey LE; DeAngelis LM; Hess KR; Lamborn KR; Prados MD; Yung WK
    J Neurooncol; 2007 Feb; 81(3):271-7. PubMed ID: 17031561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
    Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
    J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
    Zustovich F; Landi L; Lombardi G; Porta C; Galli L; Fontana A; Amoroso D; Galli C; Andreuccetti M; Falcone A; Zagonel V
    Anticancer Res; 2013 Aug; 33(8):3487-94. PubMed ID: 23898124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
    Silvani A; Lamperti E; Gaviani P; Eoli M; Fiumani A; Salmaggi A; Falcone C; Filippini G; Botturi A; Boiardi A
    J Neurooncol; 2008 Apr; 87(2):143-51. PubMed ID: 17576523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Plowman J; Waud WR; Koutsoukos AD; Rubinstein LV; Moore TD; Grever MR
    Cancer Res; 1994 Jul; 54(14):3793-9. PubMed ID: 8033099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
    Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
    Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.